FDA Approval Adds Vericiguat (Verquvo) to HF Treatment Options
The drug with a novel mechanism among HF meds is indicated for an especially high-risk group: patients with LVEF of 45% or less and a history of HF hospitalization or outpatient IV diuretic therapy. FDA Approvals